SCHEMBL3538902

SCHEMBL3538902

CC(C=O)=Cc1ccc(F)cc1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 4/20 0.43
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
GRIN2D O15399 2/20 0.42
GRIN3B O60391 2/20 0.42
GRIN1 Q05586 2/20 0.42
GRIN2A Q12879 2/20 0.42
GRIN2B Q13224 2/20 0.42
GRIN2C Q14957 2/20 0.42
GRIN3A Q8TCU5 2/20 0.42
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3538900 1.00 NFE2L2 (0.43) NFE2L2PTGS1PTGS2GRIN2DGRIN3B
SCHEMBL6394589 0.85 NFE2L2 (0.43) NFE2L2ALDH1A1TSHRPOLBMAPT
SCHEMBL6394593 0.85 NFE2L2 (0.43) NFE2L2ALDH1A1TSHRPOLBMAPT
SCHEMBL4296097 0.78 NFE2L2 (0.43) NFE2L2PTGS1PTGS2GRIN2DGRIN3B
SCHEMBL4296092 0.78 NFE2L2 (0.43) NFE2L2PTGS1PTGS2GRIN2DGRIN3B
SCHEMBL5203307 0.77 ALDH1A1 (0.53) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL28178629 0.77 ALDH1A1 (0.53) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1920614 0.76 AKR1C3 (0.44) NFE2L2PTGS1PTGS2GRIN2DGRIN3B
SCHEMBL1920181 0.76 AKR1C3 (0.44) NFE2L2PTGS1PTGS2GRIN2DGRIN3B
SCHEMBL1920180 0.76 AKR1C3 (0.44) NFE2L2PTGS1PTGS2GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144720-A1 INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-06-10 US disclosed
US-7649011-B2 Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction CHEMOCENTRYX, INC. (US) 2010-01-19 US disclosed
EP-1606251-B1 INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR CHEMOCENTRYX INC (US) 2009-04-08 EP disclosed
EP-1606251-A2 INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR ChemoCentryx Inc (US) 2005-12-21 EP disclosed
US-20040171655-A1 Inhibitors of human tumor-expressed CCXCKR2 CHEMOCENTRYX, INC. 2004-09-02 US disclosed
WO-2004058705-A2 INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR CHEMOCENTRYX (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144720-A1 INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 CCL2, CCR2, CXCR2 NFE2L2 2596/4885PTGS1 743/4885PTGS2 700/4885
US-20040171655-A1 Inhibitors of human tumor-expressed CCXCKR2 CCL2, CCR2, CXCR2 NFE2L2 2596/4885PTGS1 743/4885PTGS2 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.